Intellia Therapeutics (NTLA) EBIT Margin (2015 - 2026)
Intellia Therapeutics (NTLA) reported EBIT Margin of 668.08% for Q1 2026, up 5850.0% year-over-year from 11.23% in Q1 2025, and down 55.78% on a QoQ basis from 428.86% in Q4 2025.
Intellia Therapeutics (NTLA) has 12 years of EBIT Margin data on file, last reported at 668.08% in Q1 2026.
- Quarterly EBIT Margin rose 5850.0% year-over-year to 668.08% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 636.56% (up 55080.0% YoY) and the FY2025 annual result came in at 651.67%, up 27143.0% from the prior year.
- EBIT Margin retreated to 668.08% in Q1 2026 per NTLA's latest filing, from 428.86% in the prior quarter.
- Across five years, EBIT Margin topped out at 7297.44% in Q4 2023 and bottomed at 1998.61% in Q2 2024.
- The 5-year median for EBIT Margin is 808.86% (2025), against an average of 452.5%.
- The widest annual swing landed in 2022, when EBIT Margin jumped 2320217 bps; it then sank 835731 bps in 2024.
- Tracing NTLA's EBIT Margin over 5 years: stood at 811.07% in 2022, then surged by 1000 bps to 7297.44% in 2023, then tumbled by 115 bps to 1059.86% in 2024, then soared by 60 bps to 428.86% in 2025, then slumped by 56 bps to 668.08% in 2026.
- Per Business Quant, the three latest NTLA EBIT Margin figures stand at 668.08% (Q1 2026), 428.86% (Q4 2025), and 808.86% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | -668.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -668.08% |
| Dec 31, 2025 | -428.86% |
| Sep 30, 2025 | -808.86% |
| Jun 30, 2025 | -772.17% |
| Mar 31, 2025 | -726.57% |
| Dec 31, 2024 | -1,059.86% |
| Sep 30, 2024 | -1,588.96% |
| Jun 30, 2024 | -1,998.61% |
| Mar 31, 2024 | -394.00% |
| Dec 31, 2023 | 7,297.44% |
| Sep 30, 2023 | -1,093.29% |
| Jun 30, 2023 | -973.47% |
| Mar 31, 2023 | -888.13% |
| Dec 31, 2022 | -811.07% |
| Sep 30, 2022 | -795.49% |
| Jun 30, 2022 | -700.65% |
| Mar 31, 2022 | -1,281.96% |
| Dec 31, 2021 | -625.60% |
| Sep 30, 2021 | -23,997.67% |
| Jun 30, 2021 | -1,053.69% |
| Mar 31, 2021 | -720.33% |
| Dec 31, 2020 | -642.90% |
| Sep 30, 2020 | -126.47% |
| Jun 30, 2020 | -203.12% |
| Mar 31, 2020 | -660.96% |
| Dec 31, 2019 | -272.23% |
| Sep 30, 2019 | -238.58% |
| Jun 30, 2019 | -246.99% |
| Mar 31, 2019 | -228.21% |
| Dec 31, 2018 | -263.27% |
| Sep 30, 2018 | -325.31% |
| Jun 30, 2018 | -307.35% |
| Mar 31, 2018 | -300.31% |
| Dec 31, 2017 | -370.65% |
| Sep 30, 2017 | -216.96% |
| Jun 30, 2017 | -270.69% |
| Mar 31, 2017 | -208.33% |
| Dec 31, 2016 | -192.32% |
| Sep 30, 2016 | -158.08% |
| Jun 30, 2016 | -165.15% |
| Mar 31, 2016 | -376.70% |
| Dec 31, 2015 | -324.34% |
| Sep 30, 2015 | -195.56% |
| Jun 30, 2015 | -248.51% |
| Mar 31, 2015 | -92.92% |